ASTRAZENECA SP ADR (ZEGA MU) stock market data APIs
€69.9161
0(0%)
as of September 15, 2025
Try our APIs with
free plan!
ASTRAZENECA SP ADR Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for ZEGA.MU.
Prev. Close
69.9161
Open
69.9161
High
69.9161
Low
69.9161
52 wk Range
58.5906-72.4935
Market Cap
148 612 M
Dividends (Yield)
0.0227
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get ASTRAZENECA SP ADR data using free add-ons & libraries
Get ASTRAZENECA SP ADR Fundamental Data
ASTRAZENECA SP ADR Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
ASTRAZENECA SP ADR News
New
AstraZeneca PLC (AZN) Receives Tagrisso Boost in Lung Cancer Trials
AstraZeneca PLC (NASDAQ:AZN) is one of the best defensive stocks to buy, according to Steve Cohen. On September 7, the company announced positive clinical trial results involving Tagrisso in combinati...
Update: Market Chatter: AstraZeneca Pauses $271 Million Cambridge Project
(Updates with comments from AstraZeneca in the first paragraph and stock move in the fifth paragraph PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
AstraZeneca Pauses Plans for $271 Million Expansion of U.K. Site
The company has shelved plans for a research facility in Cambridge, a move that follows the drugmaker in January scrapping an investment in Liverpool. Continue Reading View Comments
AstraZeneca pauses £200m expansion in Cambridge
British drug giant AstraZeneca has paused a planned £200 million expansion of its research site in Cambridge, the company said. It comes after the pharmaceutical firm abandoned plans to invest £450...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
